Close this search box.

The path to precision neuropsychiatry: J&J’s perspective

ARTICLE | Product Development

From subjective symptoms to objective metrics to biological signatures, neuroscience head Bill Martin paints a trajectory of psychiatry’s path ahead 

By Selina Koch, Executive Editor 

January 31, 2024 1:36 AM UTC

It’s early days for precision medicine in neuropsychiatry, but the field is taking steps that could become an important foundation. J&J’s Bill Martin believes the path must start with robust clinical phenotyping at scale, which he sees as a prerequisite for understanding the relationship between the clinical symptoms and digital biomarkers. Predictive biological signatures will come later, he says.

As other large pharmas exited or scaled back their presence in neuropsychiatric drug development in the early 2000s, Johnson & Johnson (NYSE:JNJ) is one of the few that stayed the course. In 2019, the company brought a new mechanism to patients with treatment-resistant depression through the FDA approval of Spravato esketamine, an event that also helped pave the way for the now large pipeline of psychedelic and psychedelic-adjacent therapies in development for mental health indications. …